Chicago - Tracking the photoreactivity of many medicines that predate U.S. Food and Drug Administration requirements in this area has been an inexact science, but it's becoming less so. That's because an extensive review released in a presentation at "Important Advances in Allergy-Immunology and Dermatology - From the Bench to the Bedside," a recent gathering of allergists, immunologists and dermatologists in Chicago hosted by Northwestern University, outlines photoreactivity data for more than 100 widely used drugs gleaned from more than 150 research articles
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.